Cargando…
Pharmacokinetics of Bevacizumab in Three Patients Under the Age of 3 Years with CNS Malignancies
BACKGROUND: Bevacizumab is a recombinant antibody that is increasingly used in pediatric malignancies. The pharmacokinetics of bevacizumab in pediatric patients have been shown to be influenced by tumor localization and body weight. In this report, we present data on the pharmacokinetics and safety...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5629131/ https://www.ncbi.nlm.nih.gov/pubmed/28577293 http://dx.doi.org/10.1007/s40268-017-0190-z |